FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
about
Medical management of brain tumors and the sequelae of treatment.Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristineNelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.Busulfan in hematopoietic stem cell transplantationHigh-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.New nucleoside analogs for patients with hematological malignancies.Molecular diagnosis and risk-adjusted therapy in pediatric hematologic malignancies: a primer for pediatricians.Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup.Adolescent and young adult patients with cancer: a milieu of unique features.Current status and future directions of T-lymphoblastic lymphoma in children and adolescents.Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia.Novel therapy for childhood acute lymphoblastic leukemia.Discovery of YopE Inhibitors by Pharmacophore-Based Virtual Screening and Docking.Nelarabine associated myotoxicity and rhabdomyolysis.Adverse drug reactions triggered by the common HLA-B*57:01 variant: virtual screening of DrugBank using 3D molecular docking.Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity.
P2860
Q26992174-8ADD006F-AF89-464F-B707-4DDE28DFCAD2Q27000078-A25DB4C9-423B-43BF-873A-A4D09F7740EDQ30240892-AE40F368-0F24-4BFE-B82B-F44F7E540C64Q34668052-0759AC20-C28A-4E01-BBCA-153F21E59B6EQ37163738-FCB11255-090B-4BBE-B274-47E524A8484BQ37360025-1859B335-D38E-4071-866C-28A245189B1CQ37424784-FC74984D-0AFB-4379-8298-650539D79E9EQ37841589-0F7B95A4-BD0F-42E2-AEE6-0C0C2D98F7C6Q37847072-B31579E1-17E1-48FF-9470-2AC21F9B9322Q37963498-B739181C-05FF-452E-BE8D-244317A9BBB3Q38097334-AA0C30D6-919F-4D2A-A451-D9017A342165Q38226402-3953C3B5-D5E7-41AA-BBFB-7EF9C16BDB88Q38502885-2AD7B71C-6D68-4931-B3E1-9F26B1C9F340Q38779952-753041B4-41E3-4C1A-8988-D0BF0733830FQ39112294-1E549D4A-1C8A-4614-967B-03DF4B14C466Q39368957-23DE56FC-9BD5-45B0-9158-CFA952B8CBABQ39504677-4EABCB12-1D1D-4590-9D4B-9AE7CB430A84Q41847188-4ADD962C-CCB6-416C-8B63-03D80D3A22A6Q47703247-6710856B-36E0-4AB5-8A3A-73D5D034540EQ48298283-9D4848BD-EC91-4803-9081-813666B261F0Q54685770-DDBF53F6-C919-4C77-A087-B0F916DF9CC2
P2860
FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
FDA drug approval summary: nel ...... mphoblastic leukemia/lymphoma.
@ast
FDA drug approval summary: nel ...... mphoblastic leukemia/lymphoma.
@en
FDA drug approval summary: nelarabine
@nl
type
label
FDA drug approval summary: nel ...... mphoblastic leukemia/lymphoma.
@ast
FDA drug approval summary: nel ...... mphoblastic leukemia/lymphoma.
@en
FDA drug approval summary: nelarabine
@nl
prefLabel
FDA drug approval summary: nel ...... mphoblastic leukemia/lymphoma.
@ast
FDA drug approval summary: nel ...... mphoblastic leukemia/lymphoma.
@en
FDA drug approval summary: nelarabine
@nl
P2093
P921
P1433
P1476
FDA drug approval summary: nel ...... mphoblastic leukemia/lymphoma.
@en
P2093
John R Johnson
Martin H Cohen
Richard Pazdur
Robert Justice
P304
P356
10.1634/THEONCOLOGIST.2006-0017
P577
2008-06-01T00:00:00Z